To study the effect of lipid lowering drugs in the eye manifestations of diabetic patients

Not Applicable

Conditions: Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications

Registration Number: CTRI/2020/07/026588

Lead Sponsor: ADVANCED EYE CENTER

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Following will be the inclusion criteria:

Patients with Non proliferative diabetic retinopathy(NPDR) and clinically significant macular edema(CSME), who are treatment naÃ¯ve (not having received any form of treatment for CSME in the form of anti-VEGF, intravitreal steroids or laser therapy).

Patients who are not treatment naive, but have received any form of above mentioned therapy for CSME atleast three months prior to enrolment.

Patients who have not received any previous statin therapy (or are off statin therapy for at least six months).

4.Patients willing to give consent and come for regular follow ups.

Exclusion Criteria

Patients with proliferative diabetic retinopathy, pregnant or lactating women, patients with hepatic or renal insufficiency, any evidence of systemic inflammation or malignancy, patients with increased creatine phosphokinase or deranged liver function tests (LFTs0 or kidney function tests (KFTs) will be excluded from the study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MBER OF ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION REQUIREDTimepoint: 9 months

Secondary Outcome Measures

Name	Time	Method
BEST CORRECTED VISUAL ACUITYTimepoint: 9 MONTHS;CENTRAL MACULAR THICKNESSTimepoint: 9 MONTHS;SERUM VEGF LEVELSTimepoint: BASELINE, 3 MONTHS AND 9 MONTHS